Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Profile
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Profile
Business Name:
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Profile
Business Sector:
Short Business Description:
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Long Business Description:
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
[stock_market_widget type=”chart” symbol=”CRBP” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Country:
USA
State:
Massachusetts